Background: Hepatitis B core antibody (anti‐HBc) screening has been implemented in many blood establishments to help prevent transmission of hepatitis B virus (HBV), including from donors with occult HBV infection (OBI). We review HBV screening algorithms across blood establishments globally and their potential effectiveness in reducing transmission risk.Materials and Methods: A questionnaire on HBV screening and follow‐up strategies was distributed to members of the International Society of Blood Transfusion working party on transfusion‐transmitted infectious diseases. Screening data from 2022 were assimilated and analyzed.Results: A total of 30 unique responses were received from 25 countries. Sixteen respondents screened all donations for anti‐HBc, with 14 also screening all donations for HBV DNA. Anti‐HBc prevalence was 0.42% in all blood donors and 1.19% in new donors in low‐endemic countries; however, only 44% of respondents performed additional anti‐HBc testing to exclude false reactivity. 0.68% of anti‐HBc positive, HBsAg‐negative donors had detectable HBV DNA. Ten respondents did universal HBV DNA screening without anti‐HBc, whereas four respondents did not screen for either. Deferral strategies for anti‐HBc positive donors were highly variable. One transfusion‐transmission from an anti‐HBc negative donor was reported.Discussion: Anti‐HBc screening identifies donors with OBI but also results in the unnecessary deferral of a significant number of donors with resolved HBV infection and donors with false‐reactive anti‐HBc results. Whilst confirmation of anti‐HBc results could be improved to reduce donor deferral, transmission risks associated with anti‐HBc negative OBI donors must be considered. In high‐endemic areas, highly sensitive HBV DNA testing is required to identify infectious donors.

Objective: This work aimed to establish the effects of the COVID‐19 pandemic on blood collection and blood product usage at the end of the first year.Background: The arrival of SARS‐CoV‐2 to Colombia on March 6, 2020, triggered closure of borders and mandatory lockdown from March 23, 2020.Methods/Materials: The Colombian National Institute of Health administers the National database of confirmed cases of SARS‐CoV‐2 and the National Haemovigilance System. We examined positive SARS‐CoV‐2 cases identified between March 6, 2020, and March 6, 2021, using positive RT‐PCR testing (72.8%) or reactive antigen (27.2%). We also analysed accepted and deferred donors' information provided by 100% of blood banks and transfused patients notified by 83% of health care facilities nationwide, between March 1, 2019, to February 28, 2021.Results: Colombia registered 2 273 245 SARS‐CoV‐2 cases. From these, 60 412 people died from COVID‐19 (2.7%) and 2 172 418 individuals recovered (95.6%). There were 11 659 216 SARS‐CoV‐2 processed samples nationwide. People between the ages of 20 and 39 years concentrated 44.4% of the SARS‐CoV‐2 cases. There were 773 569 blood donations, mainly from a 20‐39‐year‐old population (60.5%). The pandemic caused a reduction of 155 393 blood donations (16.7%) and 51 823 total deferrals (33.7%).An 18.4% drop in volunteer donors and a 37.3% increase in donations from family/replacements members were observed. There were 399 453 transfused patients and 1 179 895 blood components administered (−8.7% and − 13.9% compared to March 2019–February 2020).Conclusion: Mandatory lockdowns in Colombia decreased blood collection and usage, resulting in a reduction of blood components transfused to individual patients.

Background and Objectives: Blood transfusion centres ensure the quality and safety of transfusable blood components. However, septic transfusion reactions involving environmental contaminants occur. An international survey issued by the ISBT Transfusion‐Transmitted Infectious Diseases Working Party (ISBT‐TTID‐WP) Bacterial Subgroup aimed to collect information regarding microbiological environmental monitoring from transfusion services.Materials and Methods: A Form survey (English and Spanish) with 35 questions was sent to ISBT‐TTID‐WP members. The survey had four sections: (1) respondent personal information, (2) cleaning/disinfection practices during blood component manufacturing, (3) cleaning/disinfection practices during blood component storage and (4) blood component storage bag integrity. Respondents completed the survey electronically, and data were comparatively analysed using Microsoft Excel.Results: There were 49 responses from 20 countries. Five of 49 sites manufacture blood components in a cleanroom, and most use personal protective equipment, although the type varied between sites. Approximately 40% of sites perform environmental monitoring during blood component production, with seven sites providing details about frequency and methods. Most (~94%) centres have procedures for cleaning/disinfection of processing and storage facilities with varying responses regarding areas, frequency and methods. Inconsistency was reported regarding the orientation of platelet component incubation (portrait vs. landscape). Over 93% of sites assess storage bag integrity and report damage to manufacturers, and 49% of centres report septic transfusion reactions potentially linked to damaged storage containers.Conclusion: Data from this survey highlight the need for consensual guidelines for transfusion services regarding cleaning and disinfection practices. Environmental monitoring could be adopted to minimize the risk of blood component contamination for transfusion patient safety.